Pembrolizumab vs Nivolumab as Initial Treatment for Advanced, Unresectable, or Metastatic Melanoma
This comparative effectiveness research study examines outcomes associated with pembrolizumab and nivolumab among US veterans with advanced, unresectable, or metastatic melanoma.
Authors
- Daniel A. Goldstein (ORCID: https://orcid.org/0000-0002-8082-9622)
- J.D. Nieto
- Garth William Strohbehn (ORCID: https://orcid.org/0000-0003-2973-3040)
- Alex K. Bryant (ORCID: https://orcid.org/0000-0003-0194-8381)
Institutions
- Tel Aviv University (IL)
- University of Michigan (US)
- Rabin Medical Center (IL)
- VA Center for Clinical Management Research (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-09-29
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.36432
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00